Osteoporosis following organ transplantation: pathogenesis, diagnosis and management

References

• Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos. Int.14(8), 617–630 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J. Bone Miner. Res.19(12), 1919–1932 (2004).
   PubMed Web of Science ®Google Scholar
• NIH consensus development panel on osteoporosis prevention, diagnosis and therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA285(6), 785–795 (2001).
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J. Clin. Endocrinol. Metab.90(4), 2456–2465 (2005).
   PubMed Web of Science ®Google Scholar
• Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol. Metab. Clin. North Am.36(4), 937–963; viii (2007).
   PubMed Web of Science ®Google Scholar
• Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J. Clin. Endocrinol. Metab.90(3), 1519–1524 (2005).
   PubMed Web of Science ®Google Scholar
• Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT. FGF-23 is elevated by chronic hyperphosphatemia. J. Clin. Endocrinol. Metab.89(9), 4489–4492 (2004).
   Google Scholar
• Bhan I, Shah A, Holmes J et al. Post-transplant hypophosphatemia: tertiary ‘hyper-phosphatoninism’? Kidney Int.70(8), 1486–1494 (2006).
   Google Scholar
• Ghanekar H, Welch BJ, Moe OW, Sakhaee K. Post-renal transplantation hypophosphatemia: a review and novel insights. Curr. Opin. Nephrol. Hypertens.15(2), 97–104 (2006).
   Google Scholar
• Kanaan N, Claes K, Devogelaer JP et al. Fibroblast growth factor-23 and parathyroid hormone are associated with post-transplant bone mineral density loss. Clin. J. Am. Soc. Nephrol.5(10), 1887–1892 (2010).
   PubMed Web of Science ®Google Scholar
• Torres A, Lorenzo V, Salido E. Calcium metabolism and skeletal problems after transplantation. J. Am. Soc. Nephrol.13(2), 551–558 (2002).
   PubMed Web of Science ®Google Scholar
• Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K. Abnormal bone and mineral metabolism in kidney transplant patients – a review. Am. J. Nephrol.28(2), 246–253 (2008).
   PubMed Web of Science ®Google Scholar
• Brown GG, Preisman RC, Kleerekoper M. Neurobehavioral symptoms in mild primary hyperparathyroidism: related to hypercalcemia but not improved by parathyroidectomy. Henry Ford Hosp. Med. J.35(4), 211–215 (1987).
   PubMedGoogle Scholar
• Ebeling PR. Approach to the patient with transplantation-related bone loss. J. Clin. Endocrinol. Metab.94(5), 1483–1490 (2009).
   Google Scholar
• Malluche HH, Monier-Faugere MC, Herberth J. Bone disease after renal transplantation. Nat. Rev. Nephrol.6(1), 32–40 (2010).
   PubMed Web of Science ®Google Scholar
• Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J. Am. Soc. Nephrol.11(6), 1093–1099 (2000).
   PubMed Web of Science ®Google Scholar
• Carlini RG, Rojas E, Weisinger JR et al. Bone disease in patients with long-term renal transplantation and normal renal function. Am. J. Kidney Dis.36(1), 160–166 (2000).
   PubMed Web of Science ®Google Scholar
• Cueto-Manzano AM, Konel S, Freemont AJ et al. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation. Am. J. Kidney Dis.35(2), 227–236 (2000).
   Google Scholar
• Borchhardt K, Sulzbacher I, Benesch T et al. Low-turnover bone disease in hypercalcemic hyperparathyroidism after kidney transplantation. Am. J. Transplant.7(11), 2515–2521 (2007).
   Google Scholar
• Rojas E, Carlini RG, Clesca P et al. The pathogenesis of osteodystrophy after renal transplantation as detected by early alterations in bone remodeling. Kidney Int.63(5), 1915–1923 (2003).
   PubMed Web of Science ®Google Scholar
• Lehmann G, Ott U, Stein G, Steiner T, Wolf G. Renal osteodystrophy after successful renal transplantation: a histomorphometric analysis in 57 patients. Transplant. Proc.39(10), 3153–3158 (2007).
   Google Scholar
• Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone. Ann. NY Acad. Sci.966, 73–81 (2002).
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest.102(2), 274–282 (1998).
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism32(2), 151–156 (1983).
   PubMed Web of Science ®Google Scholar
• Hahn TJ, Halstead LR, Teitelbaum SL, Hahn BH. Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration. J. Clin. Invest.64(2), 655–665 (1979).
   PubMed Web of Science ®Google Scholar
• Sakakura M, Takebe K, Nakagawa S. Inhibition of luteinizing hormone secretion induced by synthetic LRH by long-term treatment with glucocorticoids in human subjects. J. Clin. Endocrinol. Metab.40(5), 774–779 (1975).
   PubMed Web of Science ®Google Scholar
• Brandenburg VM, Ketteler M, Heussen N et al. Lumbar bone mineral density in very long-term renal transplant recipients: impact of circulating sex hormones. Osteoporos. Int.16(12), 1611–1620 (2005).
   Google Scholar
• Shane E, Rivas M, McMahon DJ et al. Bone loss and turnover after cardiac transplantation. J. Clin. Endocrinol. Metab.82(5), 1497–1506 (1997).
   PubMed Web of Science ®Google Scholar
• Monegal A, Navasa M, Guanabens N et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos. Int.12(6), 484–492 (2001).
   Google Scholar
• Floreani A, Mega A, Tizian L et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos. Int.12(9), 749–754 (2001).
   PubMed Web of Science ®Google Scholar
• Tang L, Ebara S, Kawasaki S et al. FK506 enhanced osteoblastic differentiation in mesenchymal cells. Cell Biol. Int.26(1), 75–84 (2002).
   PubMed Web of Science ®Google Scholar
• Kirino S, Fukunaga J, Ikegami S et al. Regulation of bone metabolism in immunosuppressant (FK506)-treated rats. J. Bone Miner. Metab.22(6), 554–560 (2004).
   Google Scholar
• Ponticelli C, Aroldi A. Osteoporosis after organ transplantation. Lancet357(9268), 1623 (2001).
   PubMedGoogle Scholar
• Grotz WH, Mundinger FA, Gugel B et al. Bone fracture and osteodensitometry with dual energy x-ray absorptiometry in kidney transplant recipients. Transplantation58(8), 912–915 (1994).
   PubMed Web of Science ®Google Scholar
• McIntyre HD, Menzies B, Rigby R et al. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin. Transplant.9(1), 20–24 (1995).
   PubMed Web of Science ®Google Scholar
• Cueto-Manzano AM, Konel S, Crowley V et al. Bone histopathology and densitometry comparison between cyclosporine a monotherapy and prednisolone plus azathioprine dual immunosuppression in renal transplant patients. Transplantation75(12), 2053–2058 (2003).
   PubMed Web of Science ®Google Scholar
• Josephson MA, Schumm LP, Chiu MY et al. Calcium and calcitriol prophylaxis attenuates posttransplant bone loss. Transplantation78(8), 1233–1236 (2004).
   Google Scholar
• Vautour LM, Melton LJ 3rd, Clarke BL et al. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos. Int.15(2), 160–167 (2004).
   PubMed Web of Science ®Google Scholar
• Patel S, Kwan JT, McCloskey E et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J. Bone Miner. Res.16(10), 1863–1870 (2001).
   PubMedGoogle Scholar
• Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology123(5), 2571–2577 (1988).
   PubMed Web of Science ®Google Scholar
• Schlosberg M, Movsowitz C, Epstein S et al. The effect of cyclosporin A administration and its withdrawal on bone mineral metabolism in the rat. Endocrinology124(5), 2179–2184 (1989).
   PubMed Web of Science ®Google Scholar
• [No authors listed]. Bone histology in renal transplant patients receiving cyclosporin. Lancet1(8593), 1048–1049 (1988).
   PubMedGoogle Scholar
• Bowman AR, Sass DA, Dissanayake IR et al. The role of testosterone in cyclosporine-induced osteopenia. J. Bone Miner. Res.12(4), 607–615 (1997).
   Google Scholar
• Stein B, Halloran BP, Reinhardt T et al. Cyclosporin-A increases synthesis of 1,25-dihydroxyvitamin D3 in the rat and mouse. Endocrinology128(3), 1369–1373 (1991).
   PubMed Web of Science ®Google Scholar
• Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J. Bone Miner. Res.11(1), 1–7 (1996).
   PubMed Web of Science ®Google Scholar
• Goffin E, Devogelaer JP, Lalaoui A et al. Tacrolimus and low-dose steroid immunosuppression preserves bone mass after renal transplantation. Transpl. Int.15(2–3), 73–80 (2002).
   PubMed Web of Science ®Google Scholar
• Monegal A, Navasa M, Guanabens N et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif. Tissue Int.68(2), 83–86 (2001).
   Google Scholar
• Campistol JM, Holt DW, Epstein S et al. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl. Int.18(9), 1028–1035 (2005).
   Google Scholar
• Shane E, Mancini D, Aaronson K et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am. J. Med.103(3), 197–207 (1997).
   PubMed Web of Science ®Google Scholar
• Sokhi RP, Anantharaju A, Kondaveeti R et al. Bone mineral density among cirrhotic patients awaiting liver transplantation. Liver Transpl.10(5), 648–653 (2004).
   Google Scholar
• Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl.12(9), 1390–1402 (2006).
   PubMed Web of Science ®Google Scholar
• Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: not just a cholestatic problem. Liver Transpl.9(11), 1166–1173 (2003).
   PubMed Web of Science ®Google Scholar
• Tschopp O, Boehler A, Speich R et al. Osteoporosis before lung transplantation: association with low body mass index, but not with underlying disease. Am. J. Transplant.2(2), 167–172 (2002).
   PubMed Web of Science ®Google Scholar
• Aris RM, Renner JB, Winders AD et al. Increased rate of fractures and severe kyphosis: sequelae of living into adulthood with cystic fibrosis. Ann. Intern. Med.128(3), 186–193 (1998).
   PubMed Web of Science ®Google Scholar
• Ott SM, Aitken ML. Osteoporosis in patients with cystic fibrosis. Clin. Chest Med.19(3), 555–567 (1998).
   PubMedGoogle Scholar
• Schulte C, Beelen DW, Schaefer UW, Mann K. Bone loss in long-term survivors after transplantation of hematopoietic stem cells: a prospective study. Osteoporos. Int.11(4), 344–353 (2000).
   PubMed Web of Science ®Google Scholar
• Sprague SM, Josephson MA. Bone disease after kidney transplantation. Semin. Nephrol.24(1), 82–90 (2004).
   PubMed Web of Science ®Google Scholar
• Ramsey-Goldman R, Dunn JE, Dunlop DD et al. Increased risk of fracture in patients receiving solid organ transplants. J. Bone Miner. Res.14(3), 456–463 (1999).
   PubMed Web of Science ®Google Scholar
• Almond MK, Kwan JT, Evans K, Cunningham J. Loss of regional bone mineral density in the first 12 months following renal transplantation. Nephron66(1), 52–57 (1994).
   PubMed Web of Science ®Google Scholar
• Ball AM, Gillen DL, Sherrard D et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA288(23), 3014–3018 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen A, Ebeling P, Sprague S, Shane E. Transplantation osteoporosis. In: Primer on Metabolic Diseases and Disorders of Mineral Metabolism. Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA, 302–309 (2006).
   Google Scholar
• Hay JE. Osteoporosis in liver diseases and after liver transplantation. J. Hepatol.38(6), 856–865 (2003).
   Google Scholar
• Ninkovic M, Love S, Tom BD et al. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J. Hepatol.37(1), 93–100 (2002).
   Google Scholar
• Julian BA, Laskow DA, Dubovsky J et al. Rapid loss of vertebral mineral density after renal transplantation. N. Engl. J. Med.325(8), 544–550 (1991).
   PubMed Web of Science ®Google Scholar
• Mikuls TR, Julian BA, Bartolucci A, Saag KG. Bone mineral density changes within six months of renal transplantation. Transplantation75(1), 49–54 (2003).
   PubMed Web of Science ®Google Scholar
• Leidig-Bruckner G, Hosch S, Dodidou P et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet357(9253), 342–347 (2001).
   PubMed Web of Science ®Google Scholar
• Shane R, Lazar DA, Rossi GC, Pasternak GW, Bodnar RJ. Analgesia elicited by OFQ/nociceptin and its fragments from the amygdala in rats. Brain Res.907(1–2), 109–116 (2001).
   Google Scholar
• Valimaki MJ, Kinnunen K, Volin L et al. A prospective study of bone loss and turnover after allogeneic bone marrow transplantation, effect of calcium supplementation with or without calcitonin. Bone Marrow Transplant.23(4), 355–361 (1999).
   PubMed Web of Science ®Google Scholar
• Lee WY, Cho SW, Oh ES et al. The effect of bone marrow transplantation on the osteoblastic differentiation of human bone marrow stromal cells. J. Clin. Endocrinol. Metab.87(1), 329–335 (2002).
   PubMed Web of Science ®Google Scholar
• Kang MI, Lee WY, Oh KW et al. The short-term changes of bone mineral metabolism following bone marrow transplantation. Bone26(3), 275–279 (2000).
   Google Scholar
• Brandenburg VM, Politt D, Ketteler M et al. Early rapid loss followed by long-term consolidation characterizes the development of lumbar bone mineral density after kidney transplantation. Transplantation77(10), 1566–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Pichette V, Bonnardeaux A, Prudhomme L et al. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am. J. Kidney Dis.28(1), 105–114 (1996).
   PubMedGoogle Scholar
• Cruz DN, Wysolmerski JJ, Brickel HM et al. Parameters of high bone-turnover predict bone loss in renal transplant patients: a longitudinal study. Transplantation72(1), 83–88 (2001).
   PubMed Web of Science ®Google Scholar
• El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int.67(5), 2039–2045 (2005).
   PubMed Web of Science ®Google Scholar
• Sakhaee K. Post-renal transplantation hypophosphatemia. Pediatr. Nephrol.25(2), 213–220 (2010).
   PubMed Web of Science ®Google Scholar
• Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl. Surg.5(5), 407–413 (1999).
   PubMedGoogle Scholar
• Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int.69(11), 1945–1953 (2006).
   PubMed Web of Science ®Google Scholar
• Nisbeth U, Lindh E, Ljunghall S, Backman U, Fellstrom B. Increased fracture rate in diabetes mellitus and females after renal transplantation. Transplantation67(9), 1218–1222 (1999).
   Google Scholar
• Ferreira A, Frazao JM, Monier-Faugere MC et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J. Am. Soc. Nephrol.19(2), 405–412 (2008).
   PubMed Web of Science ®Google Scholar
• Abbott KC, Oglesby RJ, Hypolite IO et al. Hospitalizations for fractures after renal transplantation in the United States. Ann. Epidemiol.11(7), 450–457 (2001).
   Google Scholar
• Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J. Clin. Endocrinol. Metab.90(3), 1294–1301 (2005).
   PubMed Web of Science ®Google Scholar
• Couttenye MM, D’Haese PC, Verschoren WJ et al. Low bone turnover in patients with renal failure. Kidney Int.56, S70–S76 (1999).
   Google Scholar
• Shane E, Rivas M, Staron RB et al. Fracture after cardiac transplantation: a prospective longitudinal study. J. Clin. Endocrinol. Metab.81(5), 1740–1746 (1996).
   Google Scholar
• Muchmore JS, Cooper DK, Ye Y et al. Prevention of loss of vertebral bone density in heart transplant patients. J. Heart Lung Transplant.11(5), 959–963; discussion 963–954 (1992).
   Google Scholar
• Berguer DG, Krieg MA, Thiebaud D et al. Osteoporosis in heart transplant recipients: a longitudinal study. Transplant Proc.26(5), 2649–2651 (1994).
   Google Scholar
• Haagsma EB, Thijn CJ, Post JG, Slooff MJ, Gips CH. Bone disease after orthotopic liver transplantation. J. Hepatol.6(1), 94–100 (1988).
   PubMed Web of Science ®Google Scholar
• Eastell R, Dickson ER, Hodgson SF et al. Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology14(2), 296–300 (1991).
   PubMed Web of Science ®Google Scholar
• Stellon AJ, Davies A, Compston J, Williams R. Bone loss in autoimmune chronic active hepatitis on maintenance corticosteroid therapy. Gastroenterology89(5), 1078–1083 (1985).
   PubMed Web of Science ®Google Scholar
• Compston JE. Hepatic osteodystrophy: vitamin D metabolism in patients with liver disease. Gut27(9), 1073–1090 (1986).
   PubMed Web of Science ®Google Scholar
• Porayko MK, Wiesner RH, Hay JE et al. Bone disease in liver transplant recipients: incidence, timing, and risk factors. Transplant Proc.23(1 Pt 2), 1462–1465 (1991).
   PubMedGoogle Scholar
• Hawkins FG, Leon M, Lopez MB et al. Bone loss and turnover in patients with liver transplantation. Hepatogastroenterology41(2), 158–161 (1994).
   Google Scholar
• Hodgson SF, Dickson ER, Wahner HW et al. Bone loss and reduced osteoblast function in primary biliary cirrhosis. Ann. Intern. Med.103(6 Pt 1), 855–860 (1985).
   PubMed Web of Science ®Google Scholar
• Bikle DD, Genant HK, Cann C et al. Bone disease in alcohol abuse. Ann. Intern. Med.103(1), 42–48 (1985).
   PubMed Web of Science ®Google Scholar
• Stellon AJ, Webb A, Compston J, Williams R. Low bone turnover state in primary biliary cirrhosis. Hepatology7(1), 137–142 (1987).
   PubMed Web of Science ®Google Scholar
• Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest109(5), 1176–1183 (1996).
   PubMed Web of Science ®Google Scholar
• Donovan DS Jr, Papadopoulos A, Staron RB et al. Bone mass and vitamin D deficiency in adults with advanced cystic fibrosis lung disease. Am. J. Respir. Crit. Care Med.157(6 Pt 1), 1892–1899 (1998).
   PubMed Web of Science ®Google Scholar
• Kananen K, Volin L, Laitinen K et al. Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J. Clin. Endocrinol. Metab.90(7), 3877–3885 (2005).
   PubMed Web of Science ®Google Scholar
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis.42(4 Suppl. 3), S1–S201 (2003).
   PubMedGoogle Scholar
• American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology125(3), 937–940 (2003).
   Google Scholar
• Compston JE. Osteoporosis after liver transplantation. Liver Transpl.9(4), 321–330 (2003).
   PubMed Web of Science ®Google Scholar
• Palmer SC, McGregor DO, Strippoli GF. Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst. Rev.3, CD005015 (2007).
   Google Scholar
• Trombetti A, Gerbase MW, Spiliopoulos A et al. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J. Heart Lung Transplant.19(8), 736–743 (2000).
   PubMedGoogle Scholar
• Hommann M, Abendroth K, Lehmann G et al. Effect of transplantation on bone: osteoporosis after liver and multivisceral transplantation. Transplant. Proc.34(6), 2296–2298 (2002).
   Google Scholar
• Shane E, Rodino MA, McMahon DJ et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study. J. Heart Lung Transplant.17(11), 1089–1096 (1998).
   PubMed Web of Science ®Google Scholar
• Talalaj M, Gradowska L, Marcinowska-Suchowierska E et al. Efficiency of preventive treatment of glucocorticoid-induced osteoporosis with 25-hydroxyvitamin D3 and calcium in kidney transplant patients. Transplant. Proc.28(6), 3485–3487 (1996).
   PubMed Web of Science ®Google Scholar
• De Sevaux RG, Hoitsma AJ, Corstens FH, Wetzels JF. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J. Am. Soc. Nephrol.13(6), 1608–1614 (2002).
   PubMed Web of Science ®Google Scholar
• El-Agroudy AE, El-Husseini AA, El-Sayed M, Ghoneim MA. Preventing bone loss in renal transplant recipients with vitamin D. J. Am. Soc. Nephrol.14(11), 2975–2979 (2003).
   Google Scholar
• Torres A, Garcia S, Gomez A et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int.65(2), 705–712 (2004).
   Google Scholar
• Garcia-Delgado I, Prieto S, Gil-Fraguas L et al. Calcitonin, etidronate, and calcidiol treatment in bone loss after cardiac transplantation. Calcif. Tissue Int.60(2), 155–159 (1997).
   PubMed Web of Science ®Google Scholar
• Van Cleemput J, Daenen W, Geusens P et al. Prevention of bone loss in cardiac transplant recipients. A comparison of biphosphonates and vitamin D. Transplantation61(10), 1495–1499 (1996).
   Google Scholar
• Cremer J, Struber M, Wagenbreth I et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann. Thorac. Surg.67(1), 130–133 (1999).
   Web of Science ®Google Scholar
• Bianda T, Linka A, Junga G et al. Prevention of osteoporosis in heart transplant recipients: a comparison of calcitriol with calcitonin and pamidronate. Calcif. Tissue Int.67(2), 116–121 (2000).
   Google Scholar
• Henderson K, Eisman J, Keogh A et al. Protective effect of short-tem calcitriol or cyclical etidronate on bone loss after cardiac or lung transplantation. J. Bone Miner. Res.16(3), 565–571 (2001).
   PubMedGoogle Scholar
• Sambrook P, Henderson NK, Keogh A et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J. Bone Miner. Res.15(9), 1818–1824 (2000).
   PubMed Web of Science ®Google Scholar
• Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int.57(2), 684–690 (2000).
   PubMed Web of Science ®Google Scholar
• Fan SL, Kumar S, Cunningham J. Long-term effects on bone mineral density of pamidronate given at the time of renal transplantation. Kidney Int.63(6), 2275–2279 (2003).
   PubMed Web of Science ®Google Scholar
• Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J. Am. Soc. Nephrol.14(10), 2669–2676 (2003).
   PubMed Web of Science ®Google Scholar
• Grotz W, Nagel C, Poeschel D et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J. Am. Soc. Nephrol.12(7), 1530–1537 (2001).
   PubMed Web of Science ®Google Scholar
• Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int.63(3), 1130–1136 (2003).
   PubMed Web of Science ®Google Scholar
• Shane E, Addesso V, Namerow PB et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med.350(8), 767–776 (2004).
   PubMed Web of Science ®Google Scholar
• Braith RW, Magyari PM, Fulton MN et al. Resistance exercise training and alendronate reverse glucocorticoid-induced osteoporosis in heart transplant recipients. J. Heart Lung Transplant.22(10), 1082–1090 (2003).
   PubMed Web of Science ®Google Scholar
• Aris RM, Lester GE, Renner JB et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. Am. J. Respir. Crit. Care Med.162(3 Pt 1), 941–946 (2000).
   PubMed Web of Science ®Google Scholar
• Stempfle HU, Werner C, Siebert U et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation73(4), 547–552 (2002).
   Google Scholar
• Crawford BA, Kam C, Pavlovic J et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med.144(4), 239–248 (2006).
   PubMed Web of Science ®Google Scholar
• Cejka D, Benesch T, Krestan C et al. Effect of teriparatide on early bone loss after kidney transplantation. Am. J. Transplant.8(9), 1864–1870 (2008).
   PubMed Web of Science ®Google Scholar
• Hay JE, Malinchoc M, Dickson ER. A controlled trial of calcitonin therapy for the prevention of post-liver transplantation atraumatic fractures in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol.34(2), 292–298 (2001).
   Google Scholar
• Valimaki MJ, Kinnunen K, Tahtela R et al. A prospective study of bone loss and turnover after cardiac transplantation: effect of calcium supplementation with or without calcitonin. Osteoporos. Int.10(2), 128–136 (1999).
   PubMed Web of Science ®Google Scholar
• Ugur A, Guvener N, Isiklar I, Karakayali H, Erdal R. Efficiency of preventive treatment for osteoporosis after renal transplantation. Transplant. Proc.32(3), 556–557 (2000).
   Google Scholar
• Stempfle HU, Werner C, Echtler S et al. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation68(4), 523–530 (1999).
   PubMed Web of Science ®Google Scholar
• Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E. Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant. Proc.34(6), 2111–2113 (2002).
   PubMed Web of Science ®Google Scholar
• Giannini S, D’Angelo A, Carraro G et al. Alendronate prevents further bone loss in renal transplant recipients. J. Bone Miner. Res.16(11), 2111–2117 (2001).
   PubMed Web of Science ®Google Scholar
• Jeffery JR, Leslie WD, Karpinski ME, Nickerson PW, Rush DN. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate. Transplantation76(10), 1498–1502 (2003).
   Google Scholar
• Krieg MA, Seydoux C, Sandini L et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos. Int.12(2), 112–116 (2001).
   Google Scholar
• Dodidou P, Bruckner T, Hosch S et al. Better late than never?. Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation. Osteoporos. Int.14(1), 82–89 (2003).
   Google Scholar
• Isoniemi H, Appelberg J, Nilsson CG et al. Transdermal oestrogen therapy protects postmenopausal liver transplant women from osteoporosis. A 2-year follow-up study. J. Hepatol.34(2), 299–305 (2001).
   PubMed Web of Science ®Google Scholar
• Fan SL, Cunningham J. Bisphosphonates in renal osteodystrophy. Curr. Opin. Nephrol. Hypertens.10(5), 581–588 (2001).
   PubMed Web of Science ®Google Scholar
• Conley E, Muth B, Samaniego M et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation86(2), 231–237 (2008).
   Google Scholar
• Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opin. Drug Saf.6(6), 663–672 (2007).
   PubMed Web of Science ®Google Scholar
• Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif. Tissue Int.41(6), 326–331 (1987).
   PubMed Web of Science ®Google Scholar
• Ribeiro A, DeVault KR, Wolfe JT 3rd, Stark ME. Alendronate-associated esophagitis: endoscopic and pathologic features. Gastrointest. Endosc.47(6), 525–528 (1998).
   PubMed Web of Science ®Google Scholar
• Watts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J. Clin. Endocrinol. Metab.95(4), 1555–1565 (2010).
   PubMed Web of Science ®Google Scholar
• Boonen S, Sellmeyer DE, Lippuner K et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int.74(5), 641–648 (2008).
   PubMed Web of Science ®Google Scholar
• Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr. Pract.12(1), 48–53 (2006).
   PubMedGoogle Scholar
• Khosla S, Burr D, Cauley J et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res.22(10), 1479–1491 (2007).
   PubMed Web of Science ®Google Scholar
• Bilezikian JP. Osteonecrosis of the jaw – do bisphosphonates pose a risk? N. Engl. J. Med.355(22), 2278–2281 (2006).
   PubMed Web of Science ®Google Scholar
• Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med.144(10), 753–761 (2006).
   PubMed Web of Science ®Google Scholar
• Shane E. Evolving data about subtrochanteric fractures and bisphosphonates. N. Engl. J. Med.362(19), 1825–1827 (2010).
   PubMed Web of Science ®Google Scholar
• Black DM, Kelly MP, Genant HK et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N. Engl. J. Med.362(19), 1761–1771 (2010).
   PubMed Web of Science ®Google Scholar
• Egbuna OI, Taylor JG, Bushinsky DA, Zand MS. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin. Transplant.21(4), 558–566 (2007).
   PubMed Web of Science ®Google Scholar
• Copley JB, Germain M, Stern L et al. Evaluation of cinacalcet HCl treatment after kidney transplantation. Transplant. Proc.42(7), 2503–2508 (2010).
   PubMed Web of Science ®Google Scholar
• Lopez V, Toledo R, Sola E et al. Treatmentwith cinacalcet in 29 kidney transplant patients with persistent hyperparathyroidism. Transplant. Proc.41(6), 2394–2395 (2009).
   Google Scholar